Regenxbio Inc. (NASDAQ:RGNX) shares are down on Wednesday after the company reported new interim data from its Phase 1/2 AFFINITY DUCHENNE trial of RGX-202.
• Regenxbio stock is among today’s weakest performers. Why is RGNX stock dropping?
Improved Motor Functions In Duchenne Patients
The latest data from REGENXBIO indicate a favorable safety and efficacy profile for RGX-202, a potential gene therapy for Duchenne muscular dystrophy.
Interim results show that pivotal dose participants improved an average of +4.9 points on the North Star Ambulatory Assessment (NSAA) compared to expected disease progression, highlighting the therapy’s potential impact.
NSAA measures functional motor abilities.
In addition, the trial demonstrated cardiac stability among participants, with key measures showing no significant decline over the treatment period.
The company expects to share topline pivotal data in the early second quarter of 2026 and plans to request a pre-BLA meeting with the FDA in mid-2026.
BioMarker Data
Biomarker data continues to support consistent, high expression and transduction of RGX-202 microdystrophin (n=13).
New data from an additional patient, aged 3.6 at dosing, had a microdystrophin expression level of 51.2% at week 12.
In February, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to the company’s Biologics License Application (BLA) for RGX-121, for Mucopolysaccharidosis II (MPS II), an ultra-rare neurodegenerative disease also known as Hunter syndrome.
Regenxbio Technical Analysis
The stock is currently trading 7.5% above its 20-day simple moving average (SMA) but is 22.6% below its 100-day SMA, indicating a struggle to maintain momentum in the longer term.
Over the past 12 months, shares have increased by 52.39%, and they are currently positioned closer to their 52-week lows than highs.
The RSI is at 51.63, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD shows a value of -0.4431, with the signal line at -0.7903, indicating bullish momentum as the MACD is above the signal line.
The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in direction.
- Key Resistance: $9.50
- Key Support: $7.50
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $28.70. Recent analyst moves include:
- HC Wainwright & Co.: Buy (Lowers target to $30 on March 9)
- Morgan Stanley: Overweight (Lowers target to $17 on March 6)
Regenxbio Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for REGENXBIO, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bullish (Score: 66.13) — Stock is outperforming the broader market.
The Verdict: REGENXBIO’s Benzinga Edge signal reveals a classic “High-Flyer” setup. While the Momentum (66.13) confirms the strong trend, the company-specific challenges highlighted in the latest trial data may require close monitoring.
RGNX Price Action: Regenxbio shares were down 4.44% at $9.46 at the time of publication on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments